# A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

> **NCT05991583** · PHASE1,PHASE2 · RECRUITING · sponsor: **SUNHO（China）BioPharmaceutical CO., Ltd.** · enrollment: 25 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** IBB0979

## Key facts

- **NCT ID:** NCT05991583
- **Lead sponsor:** SUNHO（China）BioPharmaceutical CO., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-03
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05991583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05991583, "A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05991583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*